Bionik to Present at the 9th World Congress for Neurorehabilitation
TORONTO and BOSTON, May 04, 2016 (GLOBE NEWSWIRE) -- Bionik Laboratories Corp. (OTCQX:BNKL), a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders (“Bionik” or the "Company"), announced today that Hermano I. Krebs, Ph.D., M.S., its Chief Science Officer, will present at the following events during the 9th World Congress for Neurorehabilitation being held in Philadelphia, PA from May 10 – 13, 2016.
Event: Parallel Symposia – Rehabilitation Robotics: Lower Extremity
Date: May 11, 2016 at 4:00 p.m. ET
Topic: Robotic Assistive Steppers for Locomotor Training: Trotting Back to the Starting Gate
Event: Evaluation of New Rehabilitation Technologies Forum
Date: May 12, 2016 at 4:00 p.m. ET
Topic: Evaluating Neurotechnologies: A World of Challenges and Opportunities
About 9th World Congress for Neuro Rehabilitation
The 9th World Congress, guided by the theme "From Science to Society for NeuroRehabilitation,” will cover both inspiring innovations in neurorehabilitation and their societal impacts in Philadelphia, May 10 - 13, 2016. WCNR 2016 is for all professionals involved in the multidisciplinary approach to neurorehabilitation: physicians, physical and occupational therapists, psychologists, speech therapists, rehabilitation engineers, basic neuroscientists and others. The congress will take interdisciplinary networking a step further, with symposia bridging neurorehabilitation, neurology, neurosurgery and related disciplines.
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL), is a global, pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders. Through the acquisition of Interactive Motion Technologies, Bionik has added a portfolio of products focused on upper and lower extremity rehabilitation of stroke patients. The Company now has three products on the market and three products in varying stages of development. The InMotion Systems - the InMotion ARM™, InMotion WRIST™, InMotion ARM/HAND™ and InMotion ANKLE™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. Each of Bionik’s products are or are expected to be designed to continually adapt to a patient’s ability and provide real time feedback to the physiotherapist through the use of Bionik’s proprietary data collection and analytics cloud network through its partnership with IBM.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the successful integration of IMT with Bionik and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Bionik Laboratories, Inc. Investor and Media Contact: Jenene Thomas Jenene Thomas Communications, LLC (908) 996-0239 email@example.com
Released May 4, 2016